<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The aim of this study was to measure several parameters in patients with early-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and to evaluate them for their utility in routine clinical practice </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Pre-operative serum levels of the following parameters were measured in 174 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (clinical stage I-III): carcinoembryonic antigen (CEA), carbohydrate antigen CA 19-9, proliferative marker <z:chebi fb="0" ids="17748">thymidine</z:chebi> kinase (TK), tissue <z:chebi fb="1" ids="15841">polypeptide</z:chebi> antigen (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>), tissue <z:chebi fb="1" ids="15841">polypeptide</z:chebi>-specific antigen (TPS), interleukin-6 (IL-6), interleukin-10 (IL-10), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1), vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (VCAM-1), vascular endothelial growth factor (VEGF), C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, insulin, adiponectin and leptin </plain></SENT>
<SENT sid="2" pm="."><plain>The control group consisted of 50 patients who were undergoing a complete preventive medical examination and in these patients at the time of blood collection there was no evidence of any <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> disease </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Significant increase of the following parameters was found in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>: CEA, CA 19-9, <z:chebi fb="6" ids="15702,53394">TPA</z:chebi>, IL-6, IL-10, TIMP-1, C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, insulin and adiponectin </plain></SENT>
<SENT sid="4" pm="."><plain>Only two of these, CA 19-9 and adiponectin, represent highly unfavorable prognostic factors </plain></SENT>
<SENT sid="5" pm="."><plain>If elevated, they affect both progression-free interval and overall survival </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Based on our results, we can conclude that none of the measured parameters fulfills the criteria for use for screening nor for primary diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Some of the parameters are important for prognosis estimate: Elevated CA 19-9 is related to an unfavorable prognosis, in terms of <z:e sem="disease" ids="C0920420" disease_type="Neoplastic Process" abbrv="">cancer recurrence</z:e> and mortality rate </plain></SENT>
<SENT sid="8" pm="."><plain>Angiogenetic factor VEGF represents a prognostic factor important for OS </plain></SENT>
<SENT sid="9" pm="."><plain>CEA represents a parameter which is related to disease progression </plain></SENT>
<SENT sid="10" pm="."><plain>Interleukins seem to be prospective complementary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers </plain></SENT>
<SENT sid="11" pm="."><plain>Adiponectin may be used for estimation of advanced stage of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and for estimate of risk of <z:e sem="disease" ids="C0920420" disease_type="Neoplastic Process" abbrv="">cancer recurrence</z:e> </plain></SENT>
</text></document>